The antioxidant effects of the flavonoids rutin and quercetin inhibit oxaliplatin-induced chronic painful peripheral neuropathy

Molecular Pain

Volumn 9, Issue 1, 2013, Pages

  Azevedo, Maria I ^a   Pereira, Anamaria F ^a   Nogueira, Ricardo B ^a   Rolim, Flávio E ^a   Brito, Gerly A C ^a   Wong, Deysi Viviana T ^a   Lima Júnior, Roberto C P ^a   de Albuquerque Ribeiro, Ronaldo ^a   Vale, Mariana L ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Flavonoids; Neuropathy; Oxaliplatin; Oxidative stress; Pain

Indexed keywords

MALONALDEHYDE; OXALIPLATIN; QUERCETIN; RUTOSIDE;

ALLODYNIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EXPERIMENTAL TEST; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; MOUSE; NITROSYLATION; NONHUMAN; PAIN THRESHOLD; PERIPHERAL NEUROPATHY; PRESSURE SENSE; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SPINAL CORD; STIMULUS RESPONSE; TAIL IMMERSION TEST;

ANIMALS; ANTIOXIDANTS; MALE; MICE; ORGANOPLATINUM COMPOUNDS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; QUERCETIN; RUTIN;

EID: 84886006088     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-9-53     Document Type: Article

References (49)

1. Chu E. The clinical Use of Oxaliplatin: The new member of the class. The Clinical Use of Oxaliplatin: Case Studies and Roundtable Discussion 2004, 109. Manhasset: Oncology Pub Division of CMP Healthcare Media, Marshall JL.
2. Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008, 34(4):368-377. 10.1016/j.ctrv.2008.01.003, 18281158.
3. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Brand F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
4. Van Cutsem E, Verslype C, Demedts I. The treatment of advanced colorectal cancer: where are we now and where do we go?. Best Pract Res Clin Gastroenterol 2002, 16(2):319-330. 10.1053/bega.2002.0288, 11969241.
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2003, 22:23-30. 10.1200/JCO.2004.09.046, 14665611.
6. Hurwitz HI. New agents in colon cancer. Clin Adv Hematol Oncol 2003, 7:404-405.
7. Authier N, Balayssac D, Marchand F, Ling B, Zangarelli A, Descoeur J, Coudore F, Bourinet E, Eschalier A. Animal models of chemotherapy-evoked painful peripheral neuropathies. Neurotherapeutics 2009, 6:620-629. 10.1016/j.nurt.2009.07.003, 19789067.
8. Joseph EK, Chen X, Bogen O, Levine JD. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 2008, 9(5):463-472. 10.1016/j.jpain.2008.01.335, 18359667.
9. Kaley TJ, DeAngelis LM. Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 2009, 145:3-14. 10.1111/j.1365-2141.2008.07558.x, 19170681.
10. Paice JA. Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 2009, 25(2 Suppl 1):S8-S19.
11. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007, 132(3):237-251. 10.1016/j.pain.2007.08.033, 17920770.
12. Jamieson SM, Liu J, Connor B, McKeage MJ. Oxaliplatin causes selective atrophy of a subpopulation of dorsal root ganglion neurons without inducing cell loss. Cancer Chemother Pharmacol 2005, 56(4):391-399. 10.1007/s00280-004-0953-4, 15887017.
13. Harborne JB. Nature distribution and function of plant flavonoids. Prog Clin Biol Res 1986, 213:15-24.
14. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol 1983, 32:1141-1148. 10.1016/0006-2952(83)90262-9, 6342623.
15. Morand C, Manach C, Crespy V, Remesy C. Respective bioavailability of quercetin aglycone and its glycosides in a rat mode. Biofactors 2000, 12:169-174. 10.1002/biof.5520120127, 11216481.
16. Agarwal OP. The anti-inflammatory action of nepitrin, a flavonoid. Agents Actions 1982, 12(3):298-302. 10.1007/BF01965393, 6982607.
17. Della Loggia R, Tubaro A, Dri P, Zilli C, Del Negro P. The role of flavonoids in the antiinflammatory activity of Chamomilla recutita. Prog in Clin and Biol Res 1986, 213:481-489.
18. Ferrandiz ML, Alcaraz MJ. Anti-inflammatory activity and inhibition of arachidonic acid metabolism by flavonoids. Agents Actions 1991, 32:283-288. 10.1007/BF01980887, 1650522.
19. Emim JAS, Oliveira AB, Lapa AJ. Pharmacological evaluation of the anti-inflammatory activity of a citrus bioflavonoid, hesperidin, and the isoflavonoids, duartin and claussequinone, in rats and mice. J Pharm Pharmacol 1994, 46:118-122. 10.1111/j.2042-7158.1994.tb03753.x, 8021799.
20. Di Carlo G, Mascolo N, Izzo AA, Capasso F. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 1999, 65(4):337-353. 10.1016/S0024-3205(99)00120-4, 10421421.
21. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat. Pain 2007, 128(3):225-234. 10.1016/j.pain.2006.09.016, 17084975.
22. Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001, 53(4):597-652.
23. Kovács KJ. Measurement of immediate-early gene activation- c-fos and beyond. J Neuroendocrinol 2008, 20(6):665-72. 10.1111/j.1365-2826.2008.01734.x, 18601687.
24. Herdegen T, Zimmermann M. Immediate early genes (IEGs) encoding for inducible transcription factors (ITFs) and neuropeptides in the nervous system: functional network for long-term plasticity and pain. Prog Brain Res 1995, 104:299-321.
25. Harris JA. Using c-fos as a neural marker of pain. Brain Res Bull 1998, 45:1-8. 10.1016/S0361-9230(97)00277-3, 9434195.
26. Bullitt E, Lee CL, Light AR, Willcockson H. The effect of stimulus duration on noxious-stimulus induced c-fos expression in the rodent spinal cord. Brain Res 1992, 580:172-179. 10.1016/0006-8993(92)90941-2, 1504797.
27. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987, 34:155-166. 10.1016/0163-7258(87)90009-X, 3317449.
28. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008, 13:27-46. 10.1111/j.1529-8027.2008.00156.x, 18346229.
29. Podratz JL, Knight AM, Ta LE, Staff NP, Gass JM, Genelin K, Schlattau A, Lathroum L, Windebank AJ. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 2011, 41:661-668. 10.1016/j.nbd.2010.11.017, 3031677, 21145397.
30. Vargová L, Jendelová P, Chvátal A, Syková E. Glutamate, NMDA, and AMPA induced changes in extracellular space volume and tortuosity in the rat spinal cord. J Cereb Blood Flow Metab 2001, 21(9):1077-1089.
31. Xiao WH, Zheng H, Bennett GJ. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience 2012, 17(203):194-206.
32. Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini C. Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: Could it correlate with in vivo neuropathy?. Free Radic Biol Med 2013, 31(61C):143-150.
33. Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini C. Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. J Pain 2012, 13(3):276-84. 10.1016/j.jpain.2011.11.009, 22325298.
34. Tall JM, Raja SN. Dietary constituents as novel therapies for pain. Clin J Pain 2004, 20:19-26. 10.1097/00002508-200401000-00005, 14668652.
35. Rice-Evans CA, Miller NJ, Bolwell PG, Bramley PM, Pridham JB. The relative antioxidant activities of plant-derived polyphenolic flavonoids. Free Radic Res 1995, 22(4):375-383. 10.3109/10715769509145649, 7633567.
36. Ansari MA, Abdul HM, Joshi G, Opii WO, Butterfield DA. Protective effect of quercetin in primary neurons against Aβ(1-42): relevance to Alzheimer's disease. J Nutr Biochem 2009, 20(4):269-275. 10.1016/j.jnutbio.2008.03.002, 2737260, 18602817.
37. Ishige K, Schubert D, Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinc mechanisms. Free Radic Biol Med 2001, 30(4):433-446. 10.1016/S0891-5849(00)00498-6, 11182299.
38. Sanders RA, Rauscher FM, Watkins JB. Effects of quercetin on antioxidant defense in streptozocin-induced diabetic rats. J Biochem Mol Toxicol 2001, 15(3):143-149. 10.1002/jbt.11, 11424224.
39. Singh A, Naidu PS, Kulkarni SK. Reersal of aging and chronic ethanol-induced cognitive dysfunction by quercetin a bioflavonoid. Free Radic Res 2003, 37(11):1245-1252. 10.1080/10715760310001616014, 14703737.
40. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003, 25:295-311. 10.1007/s00726-003-0018-8, 14661092.
41. Kumar A, Singh RL, Babu GN. Cell death mechanisms in the early stages of acute glutamate neurotoxicity. Neurosci Res 2010, 66(3):271-278. 10.1016/j.neures.2009.11.009, 19944120.
42. Król W, Czuba ZP, Threadgill MD, Cunningham BD, Pietsz G. Inhibition of nitric oxide (NO.) production in murine macrophages by flavones. Biochem Pharmacol 1995, 50(7):1031-1035. 10.1016/0006-2952(95)00237-T, 7575658.
43. Chen YC, Shen SC, Lee WR, Hou WC, Yang LL, Lee TJ. Inhibition of nitric oxide synthase inhibitors and lipopolysaccharide induced inducible NOS and cyclooxygenase-2 gene expressions by rutin, quercetin, and quercetin pentaacetate in RAW 264.7 macrophages. J Cell Biochem 2001, 82:537-548. 10.1002/jcb.1184, 11500931.
44. Kuhlmann MK, Horsch E, Burkhardt G, Wagner M, Köhler H. Reduction of cisplatin toxicity in cultured renal tubular cells by the bioflavonoid quercetin. Arch Toxicol 1998, 72:536-540. 10.1007/s002040050539, 9765070.
45. Middleton E. Effect of plant flavonoids on immune and inflammatory cell function. Adv Exp Med Biol 1998, 439:175-182. 10.1007/978-1-4615-5335-9_13, 9781303.
46. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16(2):109-110. 10.1016/0304-3959(83)90201-4, 6877845.
47. Cunha TM, Verri WA, Vivancos GG, Moreira IF, Reis S, Parada CA, Cunha FQ, Ferreira SH. An electronic pressure-meter nociception paw test for mice. Braz J Med Biol Res 2004, 37(3):401-407. 10.1590/S0100-879X2004000300018, 15060710.
48. Necker R, Hellon RF. Noxious thermal input from the rat tail: modulation by descending inhibitory influences. Pain 1978, 4:231-242.
49. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978, 86:271-278. 10.1016/0003-2697(78)90342-1, 655387.